Journal article
Co-delivery of ciprofloxacin and colistin using microcontainers for bacterial biofilm treatment
Department of Health Technology, Technical University of Denmark1
Drug Delivery and Sensing, Department of Health Technology, Technical University of Denmark2
Nanoprobes, Drug Delivery and Sensing, Department of Health Technology, Technical University of Denmark3
Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics, Department of Health Technology, Technical University of Denmark4
Technical University of Denmark5
Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark6
Colloids & Biological Interfaces, Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark7
Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark8
Infection Microbiology, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark9
In many infected patients, bacterial biofilms represent a mode of growth that significantly enhances the tolerance to antimicrobials, leaving the patients with difficult-to-cure infections. Therefore, there is a growing need for effective treatment strategies to combat biofilm infections. In this work, reservoir-based microdevices, also known as microcontainers (MCs), are co-loaded with two antibiotics: ciprofloxacin hydrochloride (CIP) and colistin sulfate (COL), targeting both metabolically active and dormant subpopulations of the biofilm.
We assess the effect of the two drugs in a time-kill study of planktonic P. aeruginosa and find that co-loaded MCs are superior to monotherapy, resulting in complete killing of the entire population. Biofilm consortia of P. aeruginosa grown in flow chambers were not fully eradicated. However, antibiotics in MCs work significantly faster than simple perfusion of antibiotics (62.5 ± 8.3% versus 10.6 ± 10.1% after 5 h) in biofilm consortia, showing the potential of the MC-based treatment to minimize the use of antimicrobials in future therapies.
Language: | English |
---|---|
Year: | 2021 |
Pages: | 120420 |
ISSN: | 18733476 and 03785173 |
Types: | Journal article |
DOI: | 10.1016/j.ijpharm.2021.120420 |
ORCIDs: | Birk, Stine Egebro , Mazzoni, Chiara , Borre Hansen, Morten , Molin, Søren , Hagner Nielsen, Line and Boisen, Anja |